Mar 24, 2025Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose
Feb 27, 2025Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
Jan 29, 2025Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
